Background: Mammalian target of rapamycin (mTOR) upregulation has been reported to be involved in the pathogenesis of thyroid tumors, and treatment with the mTOR inhibitor everolimus has shown promising results in endocrine tumors. We conducted a prospective phase II clinical trial to determine the efficacy and safety of everolimus in patients with advanced follicular-derived thyroid cancer.
T hyroid cancer is the most prevalent endocrine malignancy, accounting for 96% of cancers of the endocrine system and 66% of endocrine cancer mortality in 2012 (1). The current incidence in Europe is 49/1,000,000 per year, with a nearly 3 times higher incidence in women (2) . Thyroid cancer is a heterogeneous disease that is classified into differentiated thyroid carcinoma (DTC), undifferentiated (anaplastic) thyroid carcinoma (ATC), and medullary thyroid carcinoma. DTC is by far the most common (95%) subtype and includes papillary thyroid carcinoma (PTC; 80%) and follicular thyroid carcinoma (10%-15%) as well as subtypes like follicular-oncocytic thyroid carcinomas (FTC-OV). The majority of DTCs are slowly progressive and, when identified at an early stage, frequently cured with surgical management and radioactive iodine 131-I ablation (RAI) therapy. However, metastatic DTC that has become inoperable or refractory to RAI therapy is associated with a less favorable prognosis, as 10-year survival then varies between 25% and 40% (3, 4) . The efficacy of conventional chemotherapy in DTC is negligible, and chemotherapy is therefore no longer recommended in international guidelines (5, 6) . In fact, the American Thyroid Association recommends enrolling these patients in clinical trials. As a result of increased understanding of thyroid tumorigenesis, potential targets and therapeutic agents that target biological abnormalities have been identified. Until now, sorafenib and lenvatinib are the only targeted agents registered for the treatment of advanced DTC. Despite the improvement in progression-free survival (PFS) in a proportion of patients with these compounds, no effect on survival has been observed. Therefore, additional treatment options are needed for patients with progressive DTC.
Recently, several genetic alterations involving tyrosine kinase signaling pathways have been described in the pathogenesis of thyroid cancer. Activating RAS, BRAF, and TERT somatic gene variants, as well as RET/PTC rearrangements, leads to the constitutive activation of the mitogen-activated protein kinase pathway, which in turn plays a key role in the process of tumor development and progression (7) (8) (9) . In addition to the RET-RAS-RAF-MAPK signaling pathway, the (phosphatidylinositol 3-kinase)/Akt pathway is involved in the regulation of cell growth, proliferation, and survival (10) . An important downstream effector in the phosphatidylinositol 3-kinase/Akt pathway is the mammalian target of rapamycin (mTOR). Activation of the mTOR serine/ threonine protein kinase has been reported in a variety of malignant tumors with an estimated 70% of mTOR upregulation in all tumors (11) . Furthermore, mTOR was demonstrated to be activated in aggressive PTC (12) . Several studies report genomic alterations with activating effect on mTOR signaling, including MTOR, TSC1, TSC2, NF1, PTEN, and PIK3CA to induce sensitivity to mTOR inhibitors (13, 14) .
As a result of this accrued understanding of the biological basis for (differentiated) thyroid cancer development, multiple clinical trials with multitarget tyrosine kinase inhibitors have been conducted (15) . Everolimus (RAD001) is an orally available derivative of rapamycin, targeting mTOR. Everolimus exerts its activity through high-affinity interaction with an intracellular receptor protein, the immunophilin FKBP12. The FKBP12/RAD001 complex subsequently interacts with the mTOR protein kinase, inhibiting downstream signaling events involved in regulation of the G 1 -to S-phase transition (16) . The use of everolimus in neuroendocrine tumors has shown encouraging results, both in vitro and in vivo (17) (18) (19) . Recently, a phase II study of everolimus in patients with advanced thyroid cancer of all histologic subtypes (n = 38), which started simultaneously with our study, reported a partial response (PR) and durable stable disease (SD) in 5% and 45% of patients, respectively. The median PFS (mPFS) was 47 weeks (20) . Another study of everolimus in DTC (n = 31) showed 1 (3%) patient with a PR and 18 (58%) with durable SD. PFS was 16 months, and 1-year survival was 76% (21). Wagle et al. (22) showed 1 patient diagnosed with ATC derived from FTC-OV with striking response upon giving everolimus due to a homozygous somatic TSC1 variant. This patient showed relapse when the tumor was selected for a secondary somatic MTOR variant.
Our phase II study was designed to assess the efficacy and safety of everolimus in patients with progressive unresectable recurrent or metastatic differentiated thyroid carcinoma.
Materials and Methods

Patients
Eligibility criteria were the presence of per Response Evaluation Criteria in Solid Tumors 1.1 documented progressive metastases or unresectable local recurrence of DTC within 12 months before therapy for which RAI therapy was no longer effective, as indicated by prior negative posttherapeutic RAI scintigraphy (23) . Patients were required to have undergone total thyroidectomy and RAI ablative therapy and had to be $18 years of age with a Karnofsky performance score .70%. Laboratory requirements consisted of adequate bone marrow function (absolute neutrophil count $1500/mL, platelets $100,000/mL, hemoglobin $5.6 mm/L), liver function [serum bilirubin #1.53 upper limit of normal (ULN), serum alanine aminotransferase, and aspartate aminotransferase #2.53 ULN], and renal function (serum creatinine #23 ULN). Women of childbearing potential were required to have a negative serum or urinary pregnancy test within 14 days prior to the first dose of study drug. Patients were excluded when they had received prior targeted therapy with everolimus or other mTOR inhibitors. However, prior therapy with other kinase inhibitors was allowed.
Written informed consent was provided by all patients before enrollment in the trial. The study protocol was approved by the Institutional Review Board of the Leiden University Medical Center and performed in the university hospitals of Leiden and Groningen. This study was registered at Clinical-Trials.gov (NCT01118065). during the first year, thereafter every 3 months, and at study discontinuation. Additionally, patients with progressive metastases or inoperable recurrent disease of undifferentiated (anaplastic, n = 7) or medullary (n = 7) thyroid cancer were included. The same inclusion and exclusion criteria were used, apart from the criteria on RAI therapy, because this is not applicable for undifferentiated or medullary thyroid cancer. Results on the medullary thyroid carcinoma patients were published separately (24) .
Study design
Safety assessments were made every 4 weeks by adverse event collection, standard clinical and laboratory tests, and physical examinations. In case of toxicity or AEs requiring dose adjustments, drug dosing was interrupted or modified according to the protocol. The first dose reduction was to 5 mg once daily. If another dose reduction was needed, everolimus was dosed as 5 mg every other day. AE monitoring was continued for at least 4 weeks following the last dose of study treatment. The incidence, grade, and casual relationship of adverse events were graded with the use of Common Terminology Criteria for Adverse Events (version 4.0). After study discontinuation, all patients were followed for survival for 4 weeks.
Laboratory parameters
Serum thyroid-stimulating hormone, free thyroxine, thyroglobulin (Tg), Tg antibody levels, and safety parameters were assessed at all visits. Safety parameters included a total blood count as well as serum levels of sodium, potassium and creatinin, lipids, coagulation, and renal and liver function.
Somatic gene variant spectrum screening
Somatic hotspot gene variants were analyzed using a custom Ampliseq Cancer Hotspot Panel version 2 that targets 50 cancer-related genes. Furthermore, a dedicated next-generation sequencing (NGS) panel was tested targeting CDKN1A, CDKN1B, CDKN1C, CDKN2A, CDKN2B, CDKN2C, CDKN2D, NF1, and TSC1. Ion Torrent Ampliseq sequencing chemistry (Life Technologies, Foster City, CA) was used. Libraries were prepared with 10 ng genomic DNA, and each sample was uniquely barcoded using the IonXpress barcodes (Life Technologies). PGM 318 or proton P1 chips were prepared using the Ion Chef system, and sequencing was performed at the Personal Genome Machine or the Proton, respectively (Life Technologies). Gene variants were analyzed in the Geneticist Assistant NGS Interpretative Workbench (Softgenetics, version 1.1.8). Variants were classified in 5 classes; only class 4 (likely pathogenic) and class 5 (pathogenic) variants were reported.
Pharmacokinetics
To measure everolimus whole-blood concentration levels at steady-state PK, patients were admitted to the hospital for PK sampling on day 15 of treatment. Samples were collected into EDTA tubes at predose, 1 hour, 2 hours, and 3 hours after everolimus intake. Additional PK sampling at 4, 5, 6, 7, and 8 hours after everolimus intake was optional for patients. Everolimus concentrations in whole blood were measured using a validated ultra-performance liquid chromatography-tandem mass spectrometric assay. At steady-state PK, area under the concentration-time curve over the dosing interval (AUC 0-24h ), trough everolimus concentration (C trough ), time to reach peak concentration (T max ), and peak concentration (C max ) were determined using noncompartmental analyses in WinNonlin/ Phoenix version 6.3 (Pharsight, St. Louis, MO).
Statistical analysis
Sample size was based on Fleming's 1-stage design, using a significance level (one-sided) of 10% and 90% power (25) . A response rate at 24 weeks of ˂5% (P0) would not be sufficient to warrant further investigation. A response rate of 20% (P1) or more would certainly implicate further investigation of everolimus in a phase III setting. This required a total of 28 differentiated thyroid cancer patients in our study (a = 0.10, b = 0.10, P = 5%, P1 = 20%). The anaplastic thyroid cancer patients were analyzed in an explorative cohort in this study.
Endpoints are reported as median (range) or proportions. Estimates of PFS (time from starting study drug to progression or death, whichever occurred first) and OS (time from starting study drug to the date of death of any cause) with associated 95% confidence intervals (CIs) were obtained using the KaplanMeier method. Patients that were progression free and/or alive at the time of data analysis were censored. Variables influencing everolimus response were analyzed with binominal logistic regression. To determine the relation between everolimus exposure and efficacy, the patients were divided into 2 groups based on exposure above or below median everolimus exposure. Calculations were made using binominal logistic regression. The calculations were performed using SPSS 22.0 for Windows (SPSS, Chicago, IL).
Results
Anaplastic thyroid cancer
Because only 7 patients with ATC were included, no definite conclusions could be drawn. Results of this study in patients with ATC were disappointing, with none of the patients benefiting from treatment. Results on ATC patients are presented separately in Supplemental Table 1 .
Differentiated thyroid cancer
Patient characteristics
A total of 28 DTC patients was included in this study investigating the effect of everolimus in patients with progressive radioiodine refractory unresectable recurrent or metastatic thyroid carcinoma. The study started May 2010, and follow-up of the study ended on January 1, 2016. Median follow-up period was 38 months (range 2 to 64 months), and median everolimus treatment period was 11 months (range 1 to 38 months).
Baseline characteristics are listed in Table 1 . Thirteen females (46%) and 15 males (54%) were included with a median age of 64 years (range 40 to 75). The most common histological subtype was FTC-OV (28%), followed by follicular thyroid carcinoma (25%), PTC (21%), poorly differentiated PTC (11%), and follicular variant PTC (7%). After revision by our pathologist, 1 patient (4%) turned out to have an ATC. At study entry, all patients had metastatic disease. Fifteen patients (54%) were previously treated with the tyrosine kinase inhibitor sorafenib.
Efficacy
All 28 patients enrolled in this study were eligible for efficacy analysis. Data on efficacy are presented in Table 2 and Fig. 1 .
Seventeen patients (65%) showed SD as best response, with 15 (58%) having SD lasting .24 weeks. Median SD duration was 20 months (range 2 to 38 months). At the time of data analysis, 4 (15%) patients still had ongoing SD. Patients with high (.466 mg 3 h/L) everolimus whole-blood concentrations tended to have a longer median duration of SD (30 versus 11 months, P = 0.053) than patients with low everolimus whole-blood concentrations. There were no complete responses or PR. Estimated mPFS was 9 months (95% CI: 4 to 14 months) and was longer in patients with high everolimus blood concentrations (22 versus 8 months, P = 0.124). The median overall survival (OS) was 18 months (95% CI: 7 At time of data analysis, 4 patients still had ongoing SD.
doi: 10.1210/jc.2016-2525 press.endocrine.org/journal/jcemto 29 months, P = 0.272) and was not significantly influenced by everolimus whole-blood concentrations. However, the median OS was a substantial 15 months longer in patients with high everolimus whole-blood concentrations. Furthermore, in patients with bone metastases, the mPFS was significantly worse with 10 versus 30 months, P = 0.001. Disease progression and survival were not influenced by age, gender, or mutational status. Changes in Tg levels did not significantly reflect clinical outcome; however, patients with progressive disease showed a clear increase in serum Tg levels, as can be seen in Fig. 2 .
Toxicity
Thirteen patients (46%) required dose reduction due to toxicity (Supplemental Table 2 ). One patient (4%) discontinued everolimus treatment due to AEs, as he developed kidney function disorders and anemia after 11 weeks of therapy. All observed AEs are listed in Table 3 . Treatment-related AEs were predominantly grade 1 or 2, with the most common including anemia, cough, stomatitis, and hyperglycemia. Grade 3 AEs consisted of stomatitis (11%), hypertension (11%), hypocalcemia (7%), anemia (4%), hypophosphatemia (4%), anorexia (4%), and atelectasis (4%). Two grade 4 AEs were documented, as follows: 1 patient was hospitalized because of severe diarrhea, and the other due to a pneumonia. A total of 10 serious AEs was reported, none of which could be related to everolimus treatment. The fast majority of AEs were controllable with dose reduction, medication, or supporting measures. There was no relation between toxicity and performance state or age. [1 c.182A . G, p.(Gln61Arg), 1 c.183A . T, p.(Glu61His),  1 c.182A . G, p.(Gln61Arg), and 1 c.182A . G, No significant relation between mutational status and response on everolimus treatment could be determined. The 1 patient with the TSC1 variant started only 7 weeks prior to his death; therefore, the expected effects upon giving everolimus could not be monitored. However, 3 of 4 patients with an NRAS mutation and all 4 patients with a BRAF-mutated tumor showed a PFS and OS longer than the mPFS and median OS (mOS), respectively. For an overview of histology, mutational status, and response to everolimus treatment, see Supplemental Table 3 .
Pharmacokinetics
Four patients underwent the short PK sampling schedule; 22 patients participated in the extended sampling schedule. The mean concentration versus time profile with the 95% CI intervals per time point is shown in Fig. 3 .
A summary of the everolimus PK is shown in Supplemental Table 4 . The median (range) AUC 0-24h for everolimus was 466 mg 3 h/L (259 to 1336 mg 3 h/L), and the median C trough was 9.8 mg/L (5.1 to 26.3 mg/L). The median T max was 1.0 hour, and the median C max 63.6 mg/L. An independent samples Student's t test showed no significant difference in AUC 0-24h , C trough , T max , or C max based on either the limited or extended sample scheduling, and we therefore combined the data from both groups, as described previously. Due to the relative scarcity of drug concentrations in the elimination phase, we only used data from patients with the extended curve (n = 22) to calculate half-life. The median half-life of everolimus in these patients was 18.9 hours (13.1 to 35.8 hours).
The relation between everolimus and toxicity in patients with thyroid cancer was recently reported in an everolimus PK analysis in a total of 42 patients with thyroid cancer of all histological subtypes (26) .
Discussion
This phase II study was designed to assess the efficacy, safety, and PK of everolimus in patients with progressive radioiodine refractory unresectable recurrent or metastatic differentiated thyroid carcinoma. To our knowledge, this study has the longest follow-up duration compared with other studies of everolimus in patients with thyroid cancer (20) (21) (22) (23) . The results of this study are promising, with 58% of patients showing SD .24 weeks. The lack of PRs is easily explained by the fact that these tumors are slowly progressive by nature and everolimus exerts a reduced growth and proliferation effect rather than a cell death effect. The mPFS and OS were 9 and 18 months, respectively. Interestingly, patients with high everolimus whole-blood concentrations showed a longer mPFS, duration of SD, and OS compared with patients with low concentrations, albeit not significant. Furthermore, we found a significantly worse OS in patients with bone metastases. Similar results have been reported in a phase II trial with sorafenib in patients with advanced DTC (27) . The mPFS and percentage of patients with durable SD found in our study are comparable to the results of the phase III DECISION trial of sorafenib in patients with advanced DTC (28) . The phase III SELECT study of lenvatinib in patients with advanced DTC showed an mPFS of 73 weeks. The median OS was not reached; however, our median follow-up duration was twice as long (29) .
The results of the separately analyzed ATC patients were disappointing, with none of the 7 included patients showing response on everolimus treatment. Toxicity was comparable to other studies with everolimus in patients with thyroid cancer.
Somatic mutation status of genes in the mTOR pathway did not seem to stratify for response, even taking a patient with a TSC1 somatic variant into account. Tumors that are dependent on the mTOR pathway might have increased sensitivity to mTOR inhibition, and inactivating mutations in the tumor-suppressor genes TSC1 and TSC2 have been reported to result in mTOR-pathway activation (30) (31) (32) (33) . Recently, a case report was published describing a patient with an advanced ATC harboring a homozygous TSC2 mutation with a near-complete response on everolimus treatment that lasted for 18 months (22) . Furthermore, a phase II press.endocrine.org/journal/jcemstudy of everolimus in urothelial carcinoma reported a durable complete remission in a patient with a TSC1 mutation (14) . The fact that the patient with a TSC1 mutation in our study did not show a good response on everolimus treatment is probably related to extent of disease and high progression rate at trial inclusion. In addition, this could well be explained by the heterozygosity of the TSC1 mutation. Although not significant, 7 of 8 patients with BRAF or NRAS mutations showed a PFS and OS longer than the mPFS and mOS, respectively. These findings correspond with previous studies reporting on enhanced sensitivity to mTOR inhibition in a variety of RAS/BRAF-mutated tumors (13, 34, 35) . The lack of a relation between genetic analyses and response had also been observed in the decision and select trials. One of the explanations can be that genetic analyses have been performed in primary tumors that have been removed years before entering this study. The heterogeneity of genetic alterations in metastases in advanced DTC has been described recently (36) . Toxicities observed in our study were mostly grades 1 and 2 and similar to those reported in other phase II and III studies of everolimus (20) (21) (22) (37) (38) (39) (40) . Adverse effects were in the majority of cases manageable with dose reduction, medication, or supplemental measures. None of the serious AEs were related to everolimus treatment.
The PK characteristics in our study are in line with those observed in other phase I PK studies investigating everolimus 10 mg once daily (41) (42) (43) (44) . The interpatient variability in PK was also comparable to previous research.
Although everolimus is a promising agent in patients with a variety of solid tumors, it can be hypothesized that its inability to inhibit mTORC2 results in a less potent antitumor effect. An in vitro study showed simultaneous inhibition of mTORC2 during everolimus treatment resulted in greater efficacy and the prevention of requiring resistance (45) . In addition, several studies describe a feedback loop between mTOR pathway and RAS/MAPK/ERK signaling, resulting in a different prosurvival signaling pathway upon mTOR inhibition. Everolimus as a single-target agent might therefore not be the most effective therapy, emphasizing the interest of studies with everolimus combination therapy (15, 29, 31, (42) (43) (44) .
In conclusion, given the disease control rate comparable to sorafenib, but everolimus' relatively low toxicity profile, we consider everolimus to be a promising agent in the combination treatment of patients with advanced differentiated thyroid cancer, and further investigation of everolimus in sequential or combination therapy is warranted. Currently, trials combining everolimus with tyrosine kinase inhibitors are being conducted (www. clinicaltrials.gov). With the exception of a spectacular result reported recently in the literature, in the majority of ATCs there seems to be no role for everolimus treatment.
